US · Healthcare · Biotechnology
EPS came in at -0.55 against a street estimate of -0.52 — a miss of 5.8%.
Analysts rate Syndax Pharmaceuticals Inc a strong buy (12 buy, 0 hold, 0 sell out of 12) with an average price target of $37.27.
| Fund | Stake |
|---|---|
| BlackRock Inc | 10.10% |
| Kynam Capital Management, LP | 9.02% |
| The Goldman Sachs Group Inc | 6.56% |
| State Street Corp | 6.34% |
| Bank of America Corp | 4.53% |
| Vanguard Capital Management, LLC | 4.40% |
| Deerfield Management Co | 4.23% |
| Eversept Partners, LP | 3.13% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 total revenue was $83,298, compared with $45,871 in the third quarter of 2025. • Nine-month 2026 total revenue | 2026-11-02 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 total revenue was $83.3 million, up 82% year over year. • Revuforj net revenue was $60.7 million, up 90% year o | 2026-11-02 |
| Quarterly report · Q2 2026 SYNDAX PHARMACEUTICALS, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $336.5 million (June 30, 2026) vs. $134.9 million (December 31 | 2026-08-04 |
| Results announced · Q3 2026 SYNDAX PHARMACEUTICALS – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Total revenue: $72.8 million in Q2 2026, up 92% year-over-year ($37.9 million | 2026-08-04 |
| Company announcement · Q3 2026 SYNDAX PHARMACEUTICALS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Form 8-K filed July 14, 2026 by Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) • Company | 2026-07-14 |
| Material agreement · Q2 2026 SYNDAX PHARMACEUTICALS, INC. - 8-K SUMMARY HEADLINE NUMBERS • $250.0 million in aggregate principal amount of 2.25% Convertible Senior Notes issued | 2026-06-10 |
| Board / officer change · Q2 2026 SYNDAX PHARMACEUTICALS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 10, 2026 • 2026 Equity Incentive Plan approved with 7,200,000 | 2026-06-10 |
| Quarterly report · Q1 2026 SYNDAX PHARMACEUTICALS, INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash and short-term investments: $352.1 million (March 31, 2026) vs. $394.1 m | 2026-04-30 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Syndax Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.